ResearcherLund UniversityNo recent work listed
Jacob Elebro
Matched on ORCID iD 0000-0002-9550-8012; OpenAlex author ID A5020455008. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers
Papers 6
- PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. Co-author DOI 10.1002/cjp2.238↗
- Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-21-0986↗
- Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. First author DOI 10.1002/ijc.32945↗
- Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Co-author DOI 10.18632/oncotarget.23486↗
- Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Co-author DOI 10.3109/0284186x.2015.1075663↗
- Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Co-author DOI 10.1002/bjs.7574↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Karin Jirström · 5 shared papers, 2016–2022 · strength 0.55
- Paper PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. DOI 10.1002/cjp2.238↗
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Paper Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinom… DOI 10.1002/ijc.32945↗
- Jakob Eberhard · 4 shared papers, 2016–2022 · strength 0.43
- Paper PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer. DOI 10.1002/cjp2.238↗
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Paper Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomark… DOI 10.18632/oncotarget.23486↗
- Sofie Olsson Hau · 2 shared papers, 2022 · strength 0.29
- Margareta Heby · 3 shared papers, 2016–2020 · strength 0.27
- Paper Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinom… DOI 10.1002/ijc.32945↗
- Paper Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomark… DOI 10.18632/oncotarget.23486↗
- Paper Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pan… DOI 10.3109/0284186x.2015.1075663↗
- Karin Leandersson · 2 shared papers, 2020–2022 · strength 0.26
- Paper Branching Copy-Number Evolution and Parallel Immune Profiles across the Regional Tumor Space of Resected Pancreatic Can… DOI 10.1158/1541-7786.mcr-21-0986↗
- Paper Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinom… DOI 10.1002/ijc.32945↗
- Emelie Karnevi · 2 shared papers, 2018–2022 · strength 0.22
- Alexandra Petersson · 1 shared paper, 2022 · strength 0.14
- Sebastian Lundgren · 1 shared paper, 2020 · strength 0.12
- Artur Mezheyeuski · 1 shared paper, 2020 · strength 0.12
- Ann H. Rosendahl · 1 shared paper, 2011 · strength 0.04
- Roland E. Andersson · 1 shared paper, 2011 · strength 0.04
- Daniel Ansari · 1 shared paper, 2011 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.